Stockreport

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Turn Therapeutics Inc.  (TTRX) 
PDF Phase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026Secured up to $25 Million in Growth Capital from Avenue Capital G [Read more]